Breeze Holdings Acquisition Corp.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- J. Douglas Ramsey Jr., Jr.
- Full Time Employees
- 4
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 955 West John Carpenter Fwy. Irving TX United States of America 75039
- IPO Date
- Nov 24, 2020
- CIK
- 0001817640
- Similar Companies
- Business
- Breeze Holdings Acquisition Corp. is a special purpose acquisition company (SPAC) originally incorporated in 2020 and headquartered in Irving, Texas. The company focuses on effecting business combinations, mergers, and acquisitions primarily targeting innovative and high-growth sectors. In 2025, Breeze Holdings Acquisition Corp. completed a business combination with YD Biopharma Limited, a Taiwan-based clinical-stage biopharmaceutical company specializing in cancer prevention medical diagnostics and the development of exosome-based therapeutics. YD Biopharma's core products and services include cellular drugs for ophthalmology; diagnostic technologies for early detection and monitoring of pancreatic and breast cancers leveraging patented core methylation detection methods; therapeutic biologics for infectious diseases; and nutritional products. The company also serves as a clinical trial drug supplier for major pharmaceutical companies such as Novartis and holds licensing agreements for advanced diagnostic and therapeutic technologies in the U.S., European, and Asia-Pacific markets. Following the merger, the combined entity operates as YD Bio Limited, publicly traded on the Nasdaq under the ticker symbol YDES. Recent major changes include the acquisition of patents and U.S. market approval for technologies addressing eye diseases and cancer diagnostics, the establishment of a dedicated laboratory in the U.S. for pancreatic cancer detection, and the consummation of a PIPE financing raising over $11 million to support expansion and product development. The merger further positions the company for growth in healthcare markets across North America, Europe, and Asia, integrating YD Biopharma as a wholly owned subsidiary under the new holding structure YD Biopharma Holdings Limited.
Breeze Acquisition Corp. II Announces Closing of $15,000,000 Over-Allotment Option
Breeze Acquisition Corp. II Announces Pricing of $125,000,000 Initial Public Offering
Breeze Holdings Acquisition Corp. Shareholders Approve Business Combination with YD Biopharma Limited
URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Breeze Holdings Acquisition Corp. (OTC: BRZH)
Breeze Holdings Acquisition Corp. Announces Definitive Agreement to Merge with YD Biopharma Limited
Breeze Holdings Acquisition Corp. Provides Update on Trading Status and Potential Business Combination
Breeze Holdings Acquisition Corp. Announces Nasdaq Panel Approval for Continued Listing to Complete Initial Business Combination by May 28, 2024
Breeze Holdings Acquisition Corp. and TV Ammo, Inc. to Participate in the 36th Annual ROTH Conference
Breeze Holdings Acquisition Corp. and TV Ammo, Inc. Announce Filing of a Registration Statement in Connection with Proposed Business Combination
True Velocity, FN America Approaching Launch of Conversion Kits for M240
True Velocity Weapons, Suppressors and Advanced Ammo to be Displayed at SHOT Show 2024
Breeze Holdings Acquisition Corp. Announces Preliminary Vote Tabulations for Upcoming Special Meeting and Provides Update on Business Combination Timeline
True Velocity Acquires Suppressor Manufacturer Delta P Design
True Velocity Introduces Composite-Cased 5.56x45mm Cartridge for Civilians
Seraphim Space Investment Trust announces termination of merger between D-Orbit and Breeze Holdings Acquisition Corp.